Capricor Therapeutics Inc.

4.0100.00Vol 210.94K1Y Perf 154.78%
Apr 19th, 2021 15:06 DELAYED
BID3.99 ASK4.02
Open4.03 Previous Close4.01
Pre-Market- After-Market-
 - -%  - -
Target Price
10.50 
Analyst Rating
Strong Buy 1.00
Potential %
162.50 
Finscreener Ranking
★★★★+     58.29
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     54.14
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★     52.13
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap91.42M 
Earnings Rating
Neutral
Price Range Ratio 52W %
22.48 
Earnings Date
13th May 2021

Today's Price Range

3.864.07

52W Range

1.6012.32

5 Year PE Ratio Range

-2.3028.60

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-8.66%
1 Month
-24.20%
3 Months
-19.64%
6 Months
-15.93%
1 Year
154.78%
3 Years
-73.79%
5 Years
-87.35%
10 Years
-98.84%

TickerPriceChg.Chg.%
CAPR4.010.00000.00
AAPL134.510.35000.26
GOOG2 298.811.05000.05
MSFT258.89-1.8500-0.71
XOM56.33-0.3300-0.58
WFC44.130.29000.66
JNJ162.890.65000.40
FB301.58-4.6000-1.50
GE13.450.06000.45
JPM153.10-0.2000-0.13
Financial StrengthValueIndustryS&P 500US Markets
11.00
11.30
0.00
0.01
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-2 316.60
-2 286.20
-1 290.10
-
RevenueValueIndustryS&P 500US Markets
124.56K
0.01
-47.09
-40.98
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.20-
Q02 2020-0.37-0.2337.84
Q01 2020-0.36-0.3016.67
Q04 2019-0.44-0.3422.73
Q03 2019-0.70-0.4338.57
Q02 2019-0.80-0.5926.25
Q01 2019-1.10-0.8027.27
Q04 2018-1.50-1.1026.67
Earnings Per EndEstimateRevision %Trend
9/2020 QR-0.370.00-
12/2020 QR-0.360.00-
12/2020 FY-1.460.00-
12/2021 FY-0.930.00-
Next Report Date13th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume210.94K
Shares Outstanding22.80M
Trades Count905
Dollar Volume3.17M
Avg. Volume831.83K
Avg. Weekly Volume199.33K
Avg. Monthly Volume221.16K
Avg. Quarterly Volume652.25K

Capricor Therapeutics Inc. (NASDAQ: CAPR) stock closed at 4.01 per share at the end of the most recent trading day (a -0.25% change compared to the prior day closing price) with a volume of 318.12K shares and market capitalization of 91.42M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 16 people. Capricor Therapeutics Inc. CEO is Linda Marban.

The one-year performance of Capricor Therapeutics Inc. stock is 154.78%, while year-to-date (YTD) performance is 16.91%. CAPR stock has a five-year performance of -87.35%. Its 52-week range is between 1.6 and 12.32, which gives CAPR stock a 52-week price range ratio of 22.48%

Capricor Therapeutics Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 3.57, a price-to-sale (PS) ratio of 776.06, a price to cashflow ratio of 72.90, a PEG ratio of 2.32, a ROA of -58.47%, a ROC of -63.26% and a ROE of -76.63%. The company’s profit margin is -%, its EBITDA margin is -2 286.20%, and its revenue ttm is $124.56 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Capricor Therapeutics Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Capricor Therapeutics Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Capricor Therapeutics Inc. is Strong Buy (1), with a target price of $10.5, which is +162.50% compared to the current price. The earnings rating for Capricor Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Capricor Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Capricor Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.37, ATR14 : 0.55, CCI20 : -118.32, Chaikin Money Flow : -0.26, MACD : -0.61, Money Flow Index : 16.57, ROC : -13.20, RSI : 37.70, STOCH (14,3) : 3.67, STOCH RSI : 0.06, UO : 30.05, Williams %R : -96.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Capricor Therapeutics Inc. in the last 12-months were: Linda Marban (Option Excercise at a value of $153 539), Louis Manzo (Option Excercise at a value of $30 706)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a United State-based clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, and other medical conditions. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions.

CEO: Linda Marban

Telephone: +1 310 358-3200

Address: 8840 Wilshire Boulevard, Beverly HIlls 90211, CA, US

Number of employees: 16

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

54%46%

Bearish Bullish

52%48%

News

Stocktwits